Aptevo Therapeutics Inc.
APVOHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Aptevo Therapeutics Inc. focuses on Biotechnology services and products. Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the. At a $5.5M market cap, Aptevo Therapeutics Inc. ranks as a micro-cap company within healthcare. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Market Cap
$5.5M
Beta
1.67
P/E (TTM)
0.00
P/E (Fwd)
-0.21
EPS (TTM)
$1381.84
EPS (Fwd)
$-21.46
ROE
-517.9%
ROA
-118.0%
Cash
$14.5M
Total Debt
$4.4M
Free CF
-$17.2M
52W Change
-92.2%
Annual Financials
Cash vs Debt
Where APVO stands vs its 150-day and 200-day moving averages
As of the July 14, 2026 close, APVO finished 43.31% below its 150-day moving average ($7.32) and 65.59% below its 200-day moving average ($12.06). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is APVO overbought or oversold?
At the July 14, 2026 close, APVO's RSI(14) was 28.1, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Aptevo Therapeutics Inc. holds $14.5M in cash against $4.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$17.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -517.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $3.1M (2022) to $0 (2025), a 100% decline worth watching.
With a beta above 1.5, APVO tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing APVO.